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The aim of this thesis study is to ascertain if there are changes in F-18 FDG uptake 
in the liver after chemotherapy R-CHOP in patients having diffuse large B-cell non-
Hodgkin’s lymphoma. PET using 18 F-FDG is used to detect enhanced glycolysis in 
cancer cells and has proven to be valuable in diagnosis, staging and assessing 
response to therapy in a multitude of malignant disorder. PET/CT images of 19 
patients both male and female, aged between 48 to 80 years was analyzed in the 
present study. PET/CT scan of the patients were taken one week before, one week 
after, one month after and four months after chemotherapy. The images in all these 
cases were analyzed for changes in F-18 FDG uptake in liver before the treatment 
with R-CHOP and in different period after treatment. The changes were quantified 
by means of standard uptake value. The changes in standard uptake value were also 
compared with changes in liver function test before and one month after 
chemotherapy. 
The present study demonstrates there are changes in alanine aminotransferase, 
alkaline phosphatase and mean 18 F-FDG uptake in liver by R-CHOP chemotherapy 
in patients with diffuse large B-cell Non-Hodgkin’s lymphoma. However, the 
decrease in ALT and AFOS value was not significant one month after 
chemotherapy. 
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1 Introduction  
 
  The role of imaging modalities has been pivotal to the study and diagnosis of 
different diseases. In cancer studies, it plays a vital role. Especially in cases of 
aggressive cancers such as diffuse large B cell lymphoma where early detection, 
diagnosis and treatment can be lifesaving. Positron tomography coupled with Computed 
tomography has been useful in this scenario, which enables both the metabolic and 
anatomical studies to take place. Furthermore, providing functional and anatomical 
images to facilitate better diagnosis.  Diffuse Large B cell Lymphoma (DLBCL) is the 
most common type of lymphoma and accounts for 30-40% of all non-Hodgkin’s 
lymphoma cases [10]. DLBCL is a very aggressive type of Non-Hodgkin's lymphoma 
and can arise from either the lymph nodes or organs such as GI tract, skin, breast, bone, 
testes and thyroid. Due to its nature it can proliferate very fast in different part of the 
body so early identification and treatment is imperative. 
 Among various treatment techniques available to mitigate DLBCL 
chemotherapy is used widely and frequently. Administering the R-CHOP regimen to 
eradicate tumor cell is a very common practice. Apart from treating the tissue intended 
the medication has side effects on the whole body. In our study, we assess the effect of 
chemotherapy regimen on liver by measuring the standard uptake value before 
chemotherapy is administered to the patient and subsequently after each cycle of 
medication administered. Radiopharmaceutical is administered into the body which 
contains glucose and it circulates throughout the body. Tumor cells are known to 
consume more glucose than normal tissue to fuel their high rate of growth and division. 
So, as more glucose is absorbed by tumor compared to normal tissue more positrons are 
emitted from tumorous part of the body and consequently detected by positron scanner. 
The uptake of the radiopharmaceutical is different in normal and cancerous tissue, 
which can be measured via semi quantitative analysis called standard uptake value 
(SUV). In SUV injected dose, the patient’s weight and time after injection are all taken 
into account.  
 Fusion PET/CT using 18F-fluorodeoxy glucose 18F-FDG is an imaging 
technique that displays the 18F-FDG uptake throughout the body. Tumour cells are 
more active than normal cells and consume more glucose in our case 18 F FDG to fuel 
their growth and division. As more glucose in consumed more 18 F-FDG is 
phosphorylated in the tumorous region and consequently more positrons are emitted. 
The positrons are detected by the detectors in positron scanner. Areas with more activity 
are seen brighter compared to areas with lower activity. The variance of the two 
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measured activities depends on the uptake by the tissue. This difference in the uptake of 
glucose helps to separate tumorous and normal tissue. PET/CT is used not only for 
detection of cancer, but also to monitor the individual response to therapy. Changes in 
FDG accumulation in different parts of the body after treatment are seen as a useful 
marker to evaluate the effectiveness and response to therapy. 
  Accumulation of FDG in tissue can be measured by calculating the amount of 
the dose given and the weight of the patient. However, our interest is not on the overall 
accumulation of FDG in some region, but rather on the relative uptake of FDG on the 
region of interest compared to other parts of the body [13]. The SUV mean obtained 
from this process is considered reliable if the region of interest can be defined 
accurately [13]. The accurate selection of a region of interest was greatly assisted by 
implementing fusion imaging, which involved both computed tomography (CT) and 
PET images. With the aid of CT images, proper region of interest could be segmented 
and the same region of interest was applied to the PET image to get reliable SUV mean, 
SUV max values. PET/CT scan of the patients were taken one week before 
chemotherapy, one week after, one month after and three to four months after 
chemotherapy [16]. The images in all these cases were analyzed for changes in F-18 
FDG uptake in the liver before the treatment with R-CHOP and in different period after 
treatment. 
 This thesis study was undertaken to evaluate the changes in F-18 FDG uptake in  
the liver after chemotherapy RCHOP on patients having Non- Hodgkin’s lymphoma. 
The study is carried out by analyzing PET/CT scan before chemotherapy and one week, 
one month and four months after chemotherapy. The analysis also compares to liver 
based enzyme alanine aminotransferase and alkaline phosphatase value before and one 
month after treatment. 
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2 Background 
 
 
             Lymphoma is a cancer associated with the lymphatic system and lymph nodes. 
Lymphoma can be broadly classified as Hodgkin’s and non-Hodgkin’s lymphoma. The 
prevalence of Hodgkin’s and non-Hodgkin’s lymphoma accounts for 3.2% of total 
cancer cases with a mortality rate of  2.8% as per a study conducted by the International 
Agency for cancer research in 2012 [1]. The survival rate of patients with Hodgkin’s 
lymphoma is comparatively greater than patients with non-Hodgkin’s lymphoma. 
National Cancer Institute, USA predicts non-Hodgkin’s and Hodgkin’s lymphoma will 
account for total of 3.2% and 0.2%  of all cancer related death, respectively, and 
estimates  70,800 new non-Hodgkin’s lymphoma  and 9,190 Hodgkin’s lymphoma 
cases in the USA the following year [2].  
 
 
Figure 2-1 Mortality of men by different cancer types. Adapted from [47] 
Figure 2.1 shows mortality of men in Finland by different cancer in 2012.  
 
 In non-Hodgkin’s lymphoma lymphocytes T cell and B cells divide abnormally. 
Lymphoma generally involves B cell lymphocytes, which divide without control [3] 
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[24]. Some lymphomas are slow growing, whereas some grow fast and aggressively, 
which require prompt attention in regards to diagnosis and treatment  Both Hodgkin’s 
and non-Hodgkin’s lymphoma are similar in character and can be differentiated by 
biopsy. Presence of Reed-Sternberg cell in the cancer indicates the cancer is Hodgkin’s 
lymphoma. The occurrence of Hodgkin’s lymphoma has been in decline as compared to 
non-Hodgkin’s lymphoma, which has been on an increasing trend in the USA [4].  
 
 
Figure 2-1 NHL new cases Finland from 1966 to 2012. 
Mean annual number of new cancer cases of Male and female with NHL and Nodal 
NHL from 1966 to 2012.  Data adapted from [50]. 
. 
 Lymphomas are very different and diverse type of cancer and the exact cause of 
occurrence of this cancer are still unknown. The DNA mutation inherited from parent’s 
increase the chance of some cancer, but lymphoma is not the type of cancer which is 
inherited [6] [24]. As cells divide a new set of chromosomes are developed and this 
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process is not perfect, and the divided cell may have different DNA genes of the parent 
cell. Cancer may develop due to DNA mutation of tumor suppressor genes.  
 
2.1 Diffuse Large B cell lymphoma 
 It is the most common type of lymphoma and accounts for 30-40% of all non-
Hodgkin’s lymphoma cases [10]. DLBCL is an aggressive type of NHL and develops 
from B cell in the lymphatic system. There are three different types of DLBCL. 
 
2.1.1 T-cell/histiocyte-rich large B cell Lymphoma 
 
  T-cell/histiocyte-rich large B cell lymphoma can affect people of any age, but it 
is most prevalent in men over 50 years of age [15] [24]. This type of lymphoma 
accounts for less than 10% of total DLBCL cases. As the type name suggests T-cell, 
histiocytic and B cells are all involved in this form of DLBCL. It causes swelling of 
liver, spleen, lymph nodes and fever. Symptoms include swelling of the abdomen and 
discomfort. R-CHOP is used in the treatment of this lymphoma and in cases of relapsing 
high dose chemotherapy regimen or even stem cell transplant is used. 
 
2.1.2 Primary mediastinal large B cell lymphoma 
 
 Primary mediastinal large B cell lymphoma can occur to people of any age 
group, but it is most common in 25 - 40 age groups. It is more common in women than 
men. It develops in mediastinum in the chest. The mass of this cancer puts pressure on 
lungs, gut, supervene cava. This pressure leads to persistent cough, breathlessness, 
dizziness, headache, swelling of the neck and face which are the symptoms associated 
with primary mediastinal large B cell lymphoma [15] [25]. R-CHOP is used in the 
treatment of this lymphoma. High dose chemotherapy regimen or even stem cell 
transplant is used in cases of relapse. 
 
2.1.3 Intravascular Large B cell Lymphoma 
 
  Intravascular Large B cell Lymphoma is an extremely rare type of DLBCL. It 
affects people over 65 years of age. In this type of DLBCL malignant lymphocytes are 
found within small blood vessels as a result any body part can be affected but its 
occurrence in lymph node and bone marrow is very rare. It also affects the nervous 
system as a result, people have symptoms such as dizziness, weakness, loss of balance 
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change in vision, difficulty to speak and understand [15]. Treatment in patients with 
Intravascular Large B cell Lymphoma is generally high dose chemotherapy where it is 
applicable 
 
2.2 REAL classification 
 
 The classification of different type of lymphoma has been a tricky and 
challenging issue for a long period of time. For very long clinicians and scientists were 
classifying different type of lymphoma on the basis of REAL classification. Recently 
REAL classification has been revised under the initiative of WHO. This revised 
classification broadly classifies lymphomas on the basis of morphology and cell lineage 
[7].  
 
 B-cell neoplasms 
 T-cell/natural killer cell neoplasm 
 Hodgkin’s lymphoma 
 
 Lymphoma and lymphoid leukemias are both included in this classification as in 
many lymphoid neoplasms, both circulating and solid phases are present in many of the 
cases [7]. B cell neoplasms, T cell neoplasms and Hodgkin’s lymphoma have been 
categorized into different types based on immunological and genetic techniques which 
help improve understanding and treatment of various subtypes of lymphoma. As per 
data provided by cancer research UK between 2004-2011 it has been seen that almost 
half i.e. 48% of all non-Hodgkin’s lymphoma cases accounted for was a particular 
subtype of B cell neoplasm, more specifically Diffuse large cell B lymphoma. So, the 
incidence rate for diffuse large cell B lymphoma was 9 and 8 for every 100,000 men 
and women respectively [8].  In our research, we are only focusing on this particular 
subtype of Non-Hodgkin’s lymphoma. It grows fast and aggressively so prompt 
diagnosis and treatment can be life saving  
 
2.3 Symptoms 
 
 Lymphomas have very common symptoms such as painless swelling in neck, 
armpit or groin. Some people find the area of swelling aches. Apart from swelling, 
weight loss, night sweats, fever, feeling fatigued, difficulty in recovering from 
infections, itching of skin all over the body, difficulty in recovering from infections are 
symptoms associated with lymphomas [12]. Symptoms of diffuse large B cell 
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lymphoma generally depend on the site and period of development. Enlarged nodes in 
chest in patients with DLBCL can cause breathlessness or cough. Diarrhea, abdominal 
pain and bleeding in case of DLBCL in stomach [28]. 
 
2.4 Staging 
 
 After confirming the presence of lymphoma by physical examination, biopsies, 
blood test, imaging techniques, the cancer is staged into four groups according to the 
spread of cancer in the body. Ann Arbour system is used for staging lymphoma, which 
consists of four stages represented in roman numerals, followed by an alphabet which 
signifies affected organ. As per Ann Arbour staging of lymphoma cancer, it can be 
staged as: 
 
 
Table 1 Lymphoma Stages 
Stage Spread of cancer in body 
Stage I Lymphoma has affected only one lymph node area or lymphoid organ. 
Stage II Lymphoma has affected two or more groups of lymph nodes or lymphoid 
organs either above the diaphragm or below it but not on the either side. 
 
Stage III Lymphoma has affected lymph nodes above and below the diaphragm 
Stage IV Lymphoma has spread into nearby organs, bone marrow, brain, liver, spinal 
cord. 
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 During staging of lymphoma letters such as E or S or ES is used, for example 
IIIES indicates lymphoma is present on either side of the diaphragm and has spread into 
nearby organs (E) and spleen (S). 
 
 
2.5 Previous Work 
 
There have been numerous studies carried out to see the changes in SUV of liver 
and mediastinum due to R-CHOP and ACVBP chemotherapy in patients with non-
hodgkins lymphoma. Many authors have assumed liver SUV uptake to be normal and as 
a reference in their study such that 18 F-FDG accumulation on lesion greater than the 
liver at a certain point is considered abnormal [25]. It has been reported that SUV values 
of liver and mediastinum for normal cancer free patient are stable over time [46]. 
Studies by chiracvalloti et al., Ceriani et al., kaya et al. have all conducted studies to see 
changes in liver SUV due to chemotherapy. However, none of these studies have been 
able to ascertain the change is due to chemotherapy.  There have been numerous studies 
on liver and mediastinum, but no study has able to address if there are any metabolic 
change in liver due to R-CHOP chemotherapy in patients with non hodgkins lymphoma.  
 
2.6 Aim  
 
Many studies have focused on the liver and mediastinum to see changes in SUV 
before and after chemotherapy. In this thesis study, including the changes in liver SUV 
we also take into account the changes in liver based enzymes such as alanine 
aminotransferase and alkaline phosphatase. These are the enzymes most abundantly 
found in the liver and can give an indication of the health of the liver. The abnormal 
level of an enzyme in the organ can be an indication of it being under stress or disease. 
In our study, we aim to include liver function test along with liver SUV values before 
and after chemotherapy. In this way we will be able to better understand and determine 
if there are changes in liver due to chemotherapy. So the incorporation of liver function 
test with liver standard value uptake to analyse the changes due to R-CHOP 
chemotherapy will be the aim of this study.  
 
2.7 Imaging modality for diagnosis 
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 Identification of lymphoma is followed by monitoring the prevalence and spread 
of cancer around the body. The spread of cancer into various areas determine the stage 
of cancer. The staging processes categories the spread of the cancer in the body. Various 
imaging techniques and biopsies can be performed to determine the stage of cancer and 
its spread throughout the body. Imaging modalities such as CT scan, MRI, PET scan, 
PET-CT, PET/MRI and ultrasonography are used to determine the occurrence and 
spread of cancer in the body and the area affected by it. Imaging is generally followed 
by a biopsy. Biopsies are performed to confirm lymphoma. In cases where radiation can 
be an issue, especially for pregnant women, non-radiation based imaging technique such 
as MRI or ultrasonography can be used. In biopsy a small sample of bone, blood and 
bone marrow is extracted from the hipbone or breastbone and the sample is then 
analyzed to look for signs of cancer.  
 
2.7.1 Magnetic resonance Imaging 
 
  Magnetic Resonance Imaging (MRI) is an image acquisition technique 
developed in 1970s [40]. It uses a magnetic field and high energy radio frequency wave 
to obtain high quality images. MRI is a highly preferred imaging technique for soft 
tissue and in cases where ionization can be an issue. It is generally non-invasive, but in 
some cases the contrast enhancing agents can be administered for obtaining better 
contrast [41]. MRI machine consists of strong magnetic field and radio frequency wave 
generator. 
  The patient is kept inside the machine and the magnetic field switched on and 
radio pulse is generated. As the body is placed in a strong magnetic field the protons in 
the body line up to one axis. The alignment of protons in the body creates a magnetic 
vector along the axis of MRI. A radio wave is applied that causes hydrogen nuclei is 
dependent on the element and the field strength. The magnetic field is not uniform and 
varies from head to toe and by altering the local magnetic field the different slices of the 
body will resonate with different frequency. This creates the different parts of the body 
to resonate in different frequencies. As the RF source is switched off the magnetic 
vectors come back to their original state and in the process create signal which are 
received by the detector [42]. This signal is then used to create a magnetic resonance 
image.  
 Magnetic resonance takes longer acquisition time and involves variable 
protocols compared to PET/CT [39]. Studies have shown whole body MRI to be as 
effective as PET/CT in staging, localizing tumor. Whole body MRI has several 
advantages over PET/CT as it gives better contrast, soft tissue images, does not involve 
ionizing radiation and higher spatial resolution [39].  
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2.7.2 Positron Emission Tomography (PET) 
 
PET instrument consists of detectors which detect 511 Kev positrons emitted from the 
radiopharmaceutical. Of the detected positrons only collinear positrons, which strike in 
a pair are registered. The registered positrons are then used to form images using an 
iterative expectation maximization algorithm. PET imaging provides resolution of 4-5 
mm compared to 15 mm during its inception [14]. Many cancers, including lymphomas 
metabolize glucose at an abnormally high rate, which forms the basis of cancer imaging 
by 18F-FDG-PET. Cancer cells have accelerated growth as compared to normal tissue 
and to sustain such growth it has high metabolic activity. As the 18 F-FDG glucose is 
injected into the body, it is absorbed significantly high in the tumor cells as compared to 
normal cells. So, as more 18F-FDG is absorbed from the region, it emits more photons 
after positron annihilation with an electron. 
 Various radiopharmaceuticals have been in use in nuclear imaging, but the most 
common PET pharmaceutical used is Fluorine-18 (FDG). This radio pharmaceutical 
shows cellular glucose metabolism in the body. Many subtypes of lymphoma, including 
diffuse large cell B lymphoma, high grade follicular lymphoma, anaplastic large cell 
lymphoma and Burkett’s lymphoma demonstrate high glucose uptake [9]. 
 
 
Figure 2-2-2 PET scan. 
Coronal, Transverse and sagittal view of the patient under PET/CT examination. The 
figure above shows PET images which are used for segmentation to obtain standard 
uptake value.   
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  18 F-FDG is phosphorylated to 18F-FDG-6-phosphate in the tumor cells 
that cannot be further metabolized. The patient is subjected to fasting for 4-6 hours prior 
to scan and is instructed to avoid any strenuous physical activity before and after the 
radiopharmaceutical has been injected to avoid its physiological muscle uptake. FDG 
dose of 370 Mbq is injected into the patient [16]. The result can be assessed visually by 
observing low, moderate or high level of activity. Visual inspection depends from one 
observer to other results in high inter observer variability while assessing the degree of 
malignancy. So, the tumor assessment needed to be standardized which was done with a 
semi quantitative assessment using standard uptake value. The SUV is based on the 
assumption that FDG is distributed evenly throughout the body, but as normal and 
tumor cells have a different uptake level they can be differentiated which helps in 
localizing and determining malignancy of tumors [16].  
 FDG PET has been shown to be superior in specificity, sensitivity and accuracy 
as compared to CT in the staging of Hodgkin’s disease and non-Hodgkin’s lymphoma 
by as much as 85-98% [17]. SUV value obtained is also related to degree of malignancy 
and can also be used as biomarker. Study by Hutchings M et al. has shown that different 
histopathological subtype of Hodgkin's disease showed varying FDG uptake value. 
Another study further strengthened the case where grade III follicular lymphoma had 
higher FDG uptake than grade I or II [18]. FDG uptake in indolent lymphoma as 
compared to aggressive lymphoma is low [16]. The superiority of FDG-PET lies in its 
ability to detect metabolic changes in a malignant tissue before anatomical changes take 
place [16]. However, some type of low grade lymphomas (small lymphatic, nodal and 
extra nodal marginal zone, cutaneous T-cell, peripheral T-cell, primary duodenal 
follicular) show no or very low FDG uptake [19]. 
 Lack of detailed anatomical feature in FDG/PET hinders precise tumor sites. 
Localizing tumors is important for effective treatment of the lymphoma. Physiological 
uptake of FDG is high in the GI tract, urinary tract, brain, muscle, brown fat, thymus, 
salivary gland and lack of accurate anatomical detail in FDG-PET can be a huge 
problem when localizing tumor and differentiating these physiological uptake with 
tumor uptake [16]. As we discussed several factors of PET studies can make 
interpretation of result in accurate and challenging.  
 
2.7.3 Computed Tomography (CT) 
 
  Computed tomography is X-ray based imaging device which creates 
cross sectional images of any part of the body. The device is coupled with high energy 
electromagnetic source, detectors and powerful computer which work in sync to create 
high resolution images with great anatomical details. The conventional X-ray system 
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produces two dimensional data which are only useful in certain cases and does not give 
a complete picture of the imaged object. Computed tomography on the other hand, 
provides a complete image of the imaged object and we can select required slice to view 
body structure of interest.  
 Computed tomography has evolved a lot with time. Before CT was invented 
patient had to go through various radiographic examinations that included chest 
radiography, isotope scans, intravenous pyelography and various other test. Introduction 
of CT was a breakthrough in non-invasive imaging. Since its inception CT has been 
widely used in the field of staging of malignant lymphoma. Further advancement in 
computed tomography i.e. increase in speed in resolution has made it more valuable. 
Greater speed of image retrieval implies less motion and respiratory induces artifact 
[33], as a result lymph node smaller than 5 mm could be seen in whole body scan [31] 
[32]. 
  Modern CT devices are coupled with multiple detectors [29] and in 90’s spiral 
CT was introduced which further improved Computed tomography. CT is commonly 
used for staging lymphoma because of its availability and also due to cost, as it is 
relatively cost effective. CT produces excellent anatomical details of tissue and is 
pivotal in the early staging in lymphoma. Even though CT is used for initial staging it 
still has a lot of drawbacks that needs to be addressed. Unreliable in the detection of 
bone marrow disease, poor contrast of the lesion with surrounding tissue and its 
inability to detect pathological changes, makes use of computed tomography alone 
questionable [30]. So, the use of CT alone in restaging of malignant lymphoma may not 
be accurate. Use of positron emission tomography with computed tomography has been 
very effective in staging and restaging of cancer. CT provides good anatomical details 
and positron emission tomography provides functional or metabolic details. Both of the 
images than can be used together for better understanding, diagnosis and treatment of 
disease. Despite all the facts CT is still useful in staging of lymphoma, but it alone 
cannot be totally relied on in restaging phase [30]. 
  
 
2.7.4 Fusion Imaging FDG PET/CT 
 
 
 2-deoxy-2-Flourine-18fluoro-D glucose is widely tested and used 
radiopharmaceutical in positron emission tomography. Diagnosis, staging and treatment 
of cancer needs to be accurate and on time. 18F-FDG can be valuable in therapeutic 
management of patients with cancer. It provides valuable functional information 
regarding tumor. Anatomical imaging modalities show changes after there has been a 
change in the tissue, whereas functional imaging technique like 18F-FDG PET can 
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show an area of tumor before any anatomical changes. 18F-FDG is used in staging and 
restaging and is found to be more sensitive and specific for certain kind of cancers [26]. 
It has a half-life of 109.8 minutes, which makes it ideal for PET/CT scan [27]. FDG is 
glucose based radiopharmaceutical, it is not specific to any cancer, but will be 
accumulated in areas with higher metabolism, such as some muscles, nerves, 
inflammation, tumor, etc. PET scanning is usually done 60 minutes after the injection 
which allows adequate time for 18-F-FDG to get absorbed and accumulated.   
 While radiology mainly shows morphology nuclear techniques exhibit 
pathophysiology. So, the combination of both of these techniques can yield an image 
which is superior in quality and information when compared to using these modalities 
alone which is the feature of PET/CT fusion imaging. Along with a PET scanner CT 
scanner is also attached to the same device which retrieves images of the patient in 
slices around neck, chest, abdomen and pelvis. PET and CT scan the patient one after 
the other and do not work simultaneously. Then the images from both PET and CT are 
then combined to form a new image which shows distinctly if there is the presence of 
cancer and its precise location. Fusion imaging enables us to obtain images having both 
the anatomical and functional information; moreover attenuation in PET can be 
corrected by information from CT data [16]. 
  Fusion imaging has proven to be very effective in initial staging, monitoring the 
effect of therapy as well as detection of recurrence. Studies have shown accuracy of 
FDG-PET over CT in restaging of malignant lymphoma. B cell lymphoma, follicular 
lymphoma, mantle lymphoma is well visualized in routine staging and restaging [34] 
[35]. As high quality anatomical and functional images are present the examiner is more 
informed and is able to take highly accurate decisions as compared to either of the 
imaging modalities being used alone. The availability of anatomical information as well 
in form of CT slices makes it more convenient for the examiner to detect tumor sites. As 
PET images have problem with misinterpretation of physiological uptake the 
availability of anatomical information will significantly reduce false localization of 
disease. The advantage of correcting attenuation correction using CT data gives PET/CT 
fusion imaging an edge over other imaging modalities. However, in case of attenuation 
correction factors such as contrast agent, beam hardening, motion of patients can affect 
SUV values so images without attenuation correction should be included in evaluation 
[16] [20]. 
 CT images can be used for attenuation correction in PET emission data which is 
highly advantageous, as it reduces significant scanning time by 30 minutes or less [30]. 
According Kwee et al. this approach also provides low noise attenuation correction 
factors compared to PET transmission measurement when external radiation source is 
used. Problems arise when a CT contrast agent is used. Physiological motions and CT 
beam hardening effect due to metallic implant can result in alteration of the appearance 
of SUV lesion. So use of both attenuation corrected and uncorrected image should be 
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used to avoid false diagnosis and misinterpretation [36] [37].  Studies by Schaefer NG 
et al. has shown that PET/CT scan without contrast agent is sufficient for staging patient 
with Hodgkin's Disease and  aggressive Non-Hodgkin’s Lymphoma.  
 
 
 
2.8 Standard Uptake value 
 
 PET/CT is not only used for detection of cancer, but also for monitoring the 
individual response to therapy. Changes in FDG accumulation in different parts of the 
body after treatment are seen as a useful marker to evaluate the effectiveness and 
response to therapy. Accumulation of FDG in tissue can be measured by calculating the 
amount of the dose given and the weight of the patient. However, our interest is not on 
the overall accumulation of FDG in some region of interest but rather on the relative 
uptake of FDG on the region compared to other parts of the body [13]. SUV 
interpretation can be greatly affected by blood glucose level, so blood glucose level 
should be in check during PET/CT scan [49]. Study by Paquet N. has shown stable SUV 
in cancer free patients over time [46].  
 
(Standard Uptake Value) 𝑆𝑈𝑉 =  
𝑟
𝑎 𝑤⁄
 
Where, 
r: Radioactivity concentration in ROI [𝑘𝐵𝑞 𝑚𝑙⁄ ] 
a: Amount of Injected FDG [KBq] 
w: Patients weight. 
 
 
   Reconstruction of PET image is followed by analysis. During the 
analysis region of interest, i.e. liver in this case was chosen in the transverse plane on 
the entire length of the liver. The SUV mean obtained from this process is considered 
reliable if the region of interest can be defined accurately [13]. The accurate selection of 
a region of interest was greatly aided by implementing fusion imaging, which involved 
both computed tomography (CT) and PET images. With the aid of CT images proper 
region of interest could be selected and the same region of interest was applied to the 
PET image to get reliable SUV mean, SUV max values. There can also be issues with 
partial volume effect for small dimension objects. 
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2.9 Biopsy 
 
   Biopsy refers to a sample of tissue of interest taken out of the body for 
closer examination. A biopsy is generally performed after it can be determined that the 
tissue of interest is not in a normal state. The extracted sample is then further subjected 
to another mode of tests and analysis to further diagnose a disease. A biopsy is 
generally done after imaging of the area of tissue as imaging technique such as x-ray 
cannot exactly differentiate cancerous and non-cancerous tissue [43]. Various forms of 
biopsy are performed to make a cancer diagnosis. Bone marrow biopsy, needle biopsy, 
endoscopic biopsy, skin biopsy and surgical biopsy.  
  Bone marrow biopsy is performed when diagnosis related to a variety of 
blood problem is needed. It is generally performed in conditions such as lymphoma, 
leukemia and multiple myeloma. A long needle is used to extract bone marrow samples 
from back or other bones where bone marrow is present. Local anesthesia is 
administered during this procedure. In cases relating to lymphoma core needle biopsy is 
considered safe and accurate, study by Nguyen et al suggest [44] [45]. The study also 
recommends an excisional biopsy for suspicious lymphoma. 
   In endoscopic biopsy extraction tools are mounted on the endoscopic 
tube which are inserted in the body. Doctors gather visual information regarding the 
location of the tissue of interest and sample is extracted. Needle biopsy is generally 
performed when the tumor can be felt from the surface of skin such as lymph nodes or 
breast lumps. Skin biopsy is performed for skin conditions. Surgical biopsy is 
performed when above mentioned methods are not applicable and surgery is performed 
to extract sample or entire tissue which looks abnormal.  
  
 
 
2.10 Chemotherapy 
 
   Various treatment techniques have been devised which are employed 
alone or in combination with each other for most effective treatment of the Non-
Hodgkin’s lymphoma. Generally a team of doctors from different specialty team up to 
provide the best treatment possible using chemotherapy, radiotherapy, immunotherapy, 
surgery or even stem cell transplantation. The use of any one of the mentioned 
techniques or combinations of these techniques varies from patient to patient according 
to their medical condition. Some patient have indolent lymphoma, which is not harming 
the organ or its surrounding organs in such case careful and periodic examination of the 
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patient is done and treatment only begins when the patient shows symptoms tests 
indicate that cancer is getting worse.  
 
   Chemotherapy is the use of drugs to cure cancer. Chemotherapy can be 
administered orally or intravenously. Chemotherapy works by hindering the tumor cells' 
ability to grow or divide as a result the cancer cannot grow and spread. Chemotherapy is 
administered in a cycle for a set period of time where one or more combination of drugs 
is used at the same time. There are various drugs used in combination that are used to 
treat cancer. In the table below is the list of drugs that are used in combination [6]. 
 
 
 
 
Table 2 Chemotherapy Combinations 
 
 
Alkylating Agents 
Cyclophosphamide 
chlorambucil 
Bendamustine 
Ifosfamide 
 
Corticosteroids Prednisone 
Dexamethasone 
 
 
Platinum Drugs 
Cisplatin 
Carboplatin 
Oxaliplatin 
 
 
Purine Analogs 
Fludarabine 
Pentostatin 
Cladribine 
 
 
Anti-metabolites 
Cytarabine 
Gemcitabine 
Methotrexate 
Pralatrexate 
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Others 
Vincristine 
Doxorubicin 
Mitoxantrone 
Etoposide 
Bleomycin 
 
  
 
 This Table shows different medicines that are used in combination with a specific 
function for treatment of patients. Extracted from American cancer society webpage 
 
   The most common chemotherapy used in non-Hodgkin’s lymphoma is 
CHOP, which consists of four drugs cyclophosphamide, doxorubicin, vincristine and 
prednisone. Recent studies have shown that the addition of rituximab to this CHOP 
regimen works best for patient with B cell lymphoma [11]. Rituximab is an 
immunotherapy drug which is added in CHOP regimen. Other combination of drugs 
used in non-Hodgkin’s lymphoma are FAD (Fludarabine, doxorubicin, dexamethasone) 
and FMD (Fludarabine, Mitoxantrone and dexamethasone). FAD and FMD are also 
often given with rituximab [8]. Chemotherapy comes with some side effects such as 
nausea, vomiting, fatigue, risk of infection, hair and appetite loss. These side effects are 
temporary and persist only during chemotherapy treatment and go away once 
chemotherapy is over.  
 
2.11 Liver Function test 
 
  In any suspected case of the NHL blood test are carried out to see how well the 
liver and kidneys are working as these organs are in a lot of stress during any disease or 
abnormality of the body. Abnormal range of alanine aminotransferase (ALT), alkaline 
phosphatase (AFOS) and bilirubin in the blood can indicate some problem with the liver 
[21]. Diseased or damaged liver gives abnormal ALT, AFOS and bilirubin count. In this 
study, we have considered and included the values of ALT and AFOS measured before 
and after chemotherapy. These values are then correlated with the changes in SUV 
values before and after study for the same set of patients.     
 
2.11.1 ALT (Alanine Aminotransferase) 
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  Alanine Aminotransferase (ALT) is measured from blood. ALT is mainly found 
in liver and in small amount in other organs such as kidney, heart muscle and pancreas 
[22]. It is measured to see if the liver is damaged or has certain disease such as jaundice, 
hepatitis, cirrhosis.  Diseased or damaged liver releases ALT into the blood stream 
which increases the ALT level in blood. Decay of large tumor also causes high ALT 
level. It is a reliable test to determine liver damage. However, high level of ALT does 
not directly equate to liver disease or injury as mentioned above it may indicate some 
problem with the proper functioning of the liver. Knowing the exact level of ALT does 
not relate to the extent of damage or disease in liver  Its range is 10-70 U/L for male and 
10-45 U/L for female used in this study. However, the range can vary from one test 
laboratory to another. 
 
 
2.11.2 AFOS (Alkaline Phosphatase) 
 
 Alkaline Phosphatase (AFOS) is an enzyme found and measured from blood. 
This enzyme is mainly found in liver and bones. This test alone cannot indicate a 
problem with liver, but this test along with other liver function test can give us 
indication of some stress in liver due to disease or damage [23]. Its normal value ranges 
from 35-105 U/L for adults aged 18 or more. 
 
2.11.3 Prothrombin time 
 
 Prothrombin time refers to ability of blood to clot in the normal way during the 
cut, bruising or bleeding. Clotting is an important mechanism for bleeding control and 
control of blood loss from the body. It is a vital component of survival for any living 
being. These proteins or enzymes, are mainly produced in the liver called clotting 
factors. Normal values of prothrombin time is 9.5 to 13.8 seconds [38]. 
 
2.11.4 Bilirubin 
 
 Bilirubin is excreted as bile from the body. Elevation of the bile level can 
indicate abnormal liver function. Bilirubin is a by-product when red blood cells are 
damaged. Despite normal liver functioning bilirubin value can also increase due to 
destruction of red blood cells from other condition. The normal value for bilirubin 
ranges from 0.1 to 1 mg/DL [38]. 
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2.11.5 Albumin 
 
 Albumin is produced by liver alone, so abnormality in its value can indicate 
liver cirrhosis or liver disease. Albumin is readily found protein in blood. However, low 
albumin values can be caused by other conditions as well. Normal values for albumin 
are 3.5 to 5 g/dl [38]. 
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3 Material and Methods 
 
3.1 Subjects 
 
 Patients consisted of 12 male and 7 female patients, aged between 47 to 80 
years, having histologically proven aggressive Non-Hodgkin’s lymphoma. Patient in 
clinical stage II to IV, WHO performance scale better than 4 and requiring 
chemotherapy were included in the study. Patients with pregnancy, psychosis, diabetes, 
HIV infection, AIDS, primary central nervous system lymphoma or other serious 
medical conditions were excluded from the study. The blood glucose level is an 
important factor that was needed to be addressed as in patients with higher glucose level 
FDG uptake in delayed image is elevated [49].  PET/CT scan of the patients were taken 
one week before chemotherapy, one week after, one month after and three to four 
months after chemotherapy [16].  
 The images in all these cases were analyzed for changes in F-18 FDG uptake in 
liver before the treatment with R-CHOP and in different period after treatment. Written 
consent of the patients was acquired before they were included in the study; the study 
was also approved by the ethical committee of Tampere University Hospital. Patients 
then went through series of examination such as laboratory test, physical examination; 
computed tomography scans of the pelvis, chest and abdomen, unilateral bone marrow 
aspiration and trephine biopsy. After physical examination PET/CT scan of the patient 
was performed. 
 
 
 
Table 3 Patient Data 
Number Of Patients  Age 
Male 12 48-78 
P a g e  | 21 
 
 
 
Female 7 51-80 
Chemotherapy R-CHOP (19)  
Diagnosis NHL (19)  
  
 
 The table 3 illustrates the number of patients, their age, medical condition and 
mode of treatment in the present study.  
 
3.2 Scanning 
 
   PET/CT scan was carried out by Discovery STE 16, GE healthcare, 
Milwaukee, WI, USA. Prior to scanning patient were asked to fast for 6 hours and were  
administered with 370 MBq of 18 F-FDG radiopharmaceutical. 18 F FDG has a half-
life of 110 minutes. One hour after injecting radiopharmaceutical patients were 
subjected to scan from the base of the skull to the upper thigh for three minutes per bed 
position. The image obtained is then reconstructed with GE’s 3D VUE Point 
reconstruction algorithm [16].  
 The images obtained from FDG-PET/CT was evaluated quantitatively as 
standard uptake value to compare tracer uptake in different part of the body. Fusion 
imaging was used which involves both PET images and CT images for more accurate 
localization. The images were viewed in HERMES workstation which allowed multiple 
tools for viewing, manual and automatic segmentation.  
3.3 ROI selection and SUV measurement 
 
   The activity in the liver had to be quantified using standard uptake value 
(SUV). In such a scenario, there were a few techniques that could be applied to get the 
true maximum standard uptake value (SUVmax) and mean standard uptake value 
(SUVmean) values for liver. One of the technique was to select the whole liver volume 
in 3D and measure the desired value. The method used in this research was to select 
transverse slices along the length of the liver after certain interval which covered the 
entire volume of the liver. Fusion imaging mode was used where we could view and 
analyze computed tomography and positron emission tomography images dependently 
and independently.  
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Figure 3-1 Liver Transverse slice 
Transverse slices in liver were selected in uniform interval along the volume of the liver 
to get more consistent results for all the image studies, as shown in figure 3-1. 
 
           The selection of liver ROI using only PET was tricky and subject to 
error. So, computed tomography was used to select transverse slices at every 10 mm 
thickness. Region of interest was then manually selected in each of the transverse slices. 
To make the measurement more reliable region of interest was made constant wherever 
possible for consecutive slices provided the region was well inside the liver boundary. 
Manual segmentation of the slices was challenging, but the use of computed 
tomography to locate the exact boundary of the liver simplified the task, moreover it 
made the obtained standard uptake value of the liver more reliable. 
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Figure 3-2 Manual Segmentation 
 Manual selection of transverse liver slice as shown in figure 3-2 to obtain mean 
and max standard uptake value along with coronal and sagittal view of the patient to 
better facilitate ROI selection in HERMES workstation.  
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Figure 3-3 ROI selection 
 Figure 3-3 shows manual transverse liver slice selection to obtain SUV values in 
an FDG-PET scan on HERMES workstation. The standard uptake value of the selected 
region of interest was obtained.  
 
 To be exactly precise fusion imaging technique was applied, which used 
computed tomography and positron emission tomography so that only the liver slices 
were selected and other structures were not included in the ROI.  
 
3.4 Statistical Analysis 
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 Statistical analysis is a vital component of the whole analysis. The standard 
uptake value of the liver slices obtained from the Hermes workstation had to be 
processed to obtain the standard uptake value of the whole liver not the slices. The 
region of interest in liver slices was selected and assessed using standard protocol. To 
obtain the SUV of whole liver volume, mean of the all the slices was calculated which 
is represented as SUVmean in our study. The maximum SUV however, was selected 
among the highest registered SUV among all slices.  
  The study included 19 patients each with four PET/CT scans one before 
administrating chemotherapy and three scans after chemotherapy. 76 scans were studied 
in the process to obtain the mean and maximum standard uptake value of liver in each 
case. IBM SPSS 22 software was used to statistically analyze the changes in mean and 
maximum SUV before chemotherapy and after chemotherapy. Liver function tests were 
also carried out for patients during the time of the scan. In this study, we have included 
ALT and AFOS value at baseline and one month after chemotherapy, which was taken 
from the patients’ blood sample on the same day of the scan. The paired T test was used 
to assess if the changes in the enzymes value varied significantly before and after 
chemotherapy. The paired T test was also used to see changes in the SUV mean and 
SUVmaximum value during the same time period.  
 
 
Figure 3-4: Baseline (E1) 
PET/CT scans showing coronal, transverse and sagittal slice of patient               before 
chemotherapy as illustrated in figure 3-4. Arrow indicating liver, which is the region 
of interest in our study.  
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Figure 3-3-5 : One week after Chemotherapy (E2) 
PET/CT scans showing coronal, transverse and sagittal slice of patient               one 
week after chemotherapy, as illustrated in figure 3-5. 
 
Figure 3-6: One month after chemotherapy (E3) 
PET/CT scans showing coronal, transverse and sagittal slice of patient               one 
month after chemotherapy, as shown in figure 3-6. 
P a g e  | 27 
 
 
 
 
Figure 3-7:Four months After chemotherapy (E4) 
Figure 3-7 PET/CT scans showing coronal, transverse and sagittal slice of patient               
four months after chemotherapy. 
 
 The difference in result is determined using p value. P value less than 0.05 
represents there is a significant difference between the mean of the tested values. If the 
p value is more than 0.05 it represents there is no significant difference in the mean 
values before and after treatment. 
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4 Results 
 
4.1 Mean and Maximum SUV of Liver 
   The table below shows the mean and maximum liver standard uptake 
value obtained after manual segmentation of transverse liver slices from PET/CT scan 
of all 19 patients. In the study, PET/CT scan was taken before chemotherapy and three 
scans were carried out after chemotherapy. As we can see from the table some of the 
patients did not appear for certain PET/CT scans after chemotherapy, but we still 
decided to include them in the study as it may not affect the outcome of the study 
considerably.  
 
Table 4 Mean and Maximum SUV of Liver 
  Mean SUV Maximum SUV 
Patient E1 E2 E3 E4 E1 E2 E3 E4 
1 1,6745 1,7323 2,0177 1,8864 1,0814 4,2412 3,0270 3,2980 
2 1,9366 1,8596 1,9623 2,1268 1,2969 4,4780 3,2200 3,1050 
3 1,9752 - 1,9021 1,8608 1,3100 - 3,0180 4,7610 
4 1,8088 1,9826 1,5061 2,2395 1,0604 3,2200 2,8680 4,0950 
5 1,4604 1,7713 1,6295 1,9649 ,6651 3,5350 2,5180 2,9540 
6 1,9942 - 2,2577 1,9498 ,8800 - 3,8970 3,8020 
7 2,3139 2,3257 2,4822 2,4744 1,2317 3,2900 4,1820 3,6030 
8 2,1142 1,9956 2,2564 2,7626 1,4317 3,0420 4,1190 4,1810 
9 1,3328 1,7352 1,6175 1,8353 ,5126 2,5580 2,7460 2,8040 
10 1,5219 1,9509 1,8043 2,0160 ,8506 3,1520 3,5810 3,3920 
11 1,7063 1,4437 1,8447 1,7990 1,1899 2,1110 2,5390 2,8510 
12 1,2971 1,8998 - 1,7204 ,6500 2,9710 - 3,7460 
13 2,0317 2,4440 2,2881 1,9453 ,9478 3,3310 3,6230 2,8950 
14 2,3614 2,4403 2,4453 2,3676 1,0870 3,6370 3,8950 4,0180 
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15 2,0700 2,0367 2,2817 2,3599 1,2184 3,3320 3,9780 3,5790 
16 1,9690 1,9029 2,2173 2,2751 ,9304 3,8290 4,2950 3,8520 
17 2,6505 2,5156 2,5562 2,3357 1,6702 5,0160 4,7240 4,3590 
18 3,0756 2,9858 2,9632 3,2795 ,8000 6,1510 5,8350 5,1410 
19 1,8342 1,8214 2,0340 2,0691 1,1052 2,8215 3,0777 3,1972 
 
 
Table shows mean and maximum standard uptake value for liver for 19 patients at 
baseline (E1), one week after chemotherapy (E2), one month after chemotherapy (E3) 
and four months after chemotherapy (E4).  
 
4.2 Liver SUV Mean before and after treatment 
 
   Mean liver standard uptake value is compared using a paired T test 
before treatment and after different cycles of administering R-CHOP chemotherapy. 
The test is carried out using IBM SPSS 22 software. Comparing means before treatment 
and one week after chemotherapy we obtained a P value of 0.109. Significance limit in 
our hypothesis has α = 0.05, which is smaller than our obtained P value. Hence, we can 
say that there is no significant difference in the mean SUV before treatment and one 
week after treatment.  
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Figure 4-1: Mean SUV 
Plot 4-1 shows mean standard uptake value for liver at baseline (E1), one week after 
chemotherapy (E2), one month after chemotherapy (E3) and four months after 
chemotherapy. The black line in each box indicates the mean of liver SUV means.  
 
 A similar test is carried out and SUV before treatment is compared to one month 
and four months after treatment. The mean standard uptake value one month and four 
months after treatment was highly significant, where calculated P value was 0.005 and 
0.001 respectively when compared to baseline PET/CT. We could infer that there is a 
noticeable change in the mean standard uptake value in that period.  
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Table 5: T paired Test mean SUV 
 
 
 Paired sample T test carried out on mean standard uptake value obtained at baseline 
(E1), one week after chemotherapy (E2), one month after chemotherapy (E3) and four 
months after chemotherapy (E4) in the liver. Sig represents a significance level 
calculated from the test carried out on IBM SPSS 22.  
 
   After chemotherapy started on the patient, we again evaluated the 
changes in liver SUV. Three distinct PET/CT studies were carried out one week, one 
month and four months after treatment. Mean SUV of all the studies was compared and 
we could statistically see that there was no significant change in the mean SUV value. 
The complete table for t pair test is attached in appendix. This study demonstrates that 
after administrating R-CHOP chemotherapy the mean liver standard uptake value did 
not change when compared to one month and four months after chemotherapy. 
 
4.3 Liver SUV max before and after treatment 
 
  A paired T test was carried out in IBM SPSS 22 software to statistically test the 
changes in maximum standard uptake value before treatment and after chemotherapy in 
liver. All cases were tested in pairs to find if there was any significant difference in the 
liver maximum SUV value. Correlation between liver function test and standard uptake 
value of liver was carried out using MedCalc software.  
 
 
Table 6: Paired T test Maximum SUV 
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Paired sample T test carried out on the maximum standard uptake value obtained at 
baseline (E1), one week after chemotherapy (E2), one month after chemotherapy (E3) 
and four months after chemotherapy (E4) in the liver. Sig represents a significance level 
calculated from the test carried out on IBM SPSS 22.  
 
  There was no significant difference in the maximum standard uptake value in all 
the cases. The test result attached in appendix clearly shows no significant rise in the 
maximum SUV value in all the cases before and after treatment.  
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Figure 4-2: Maximum SUV 
Plot 4-2 shows maximum standard uptake value for liver at baseline (E1)  one week 
after chemotherapy (E2) one month after chemotherapy (E3) and four months after 
chemotherapy in liver. The black line in each box indicates the mean of liver SUV 
maximum. 
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4.4 Liver Standard Uptake Value and Liver Function 
Test 
4.4.1 Mean SUV and Alanine Aminotransferase: 
 Liver function test helps to determine and show us any 
abnormality that may persist in the liver due to disease or injury. It is very common for 
liver to show stress during such period which is reflected in the abnormal or high level 
of some enzyme in blood. In this study alanine aminotransferase (ALT) and alkaline 
phosphatase (AFOS) are the two enzymes included which are vital components of liver 
function test. ALT is mainly found in liver and in small amounts in other organs. AFOS 
are also found mainly in liver and bones. So, examining the level of these enzymes can 
give us vital clues as in relation to the condition of the liver. ALT and AFOS enzyme 
level in blood is examined before and after chemotherapy, in order to see if any pattern 
or relation between these values that may help in future diagnosis of diffuse large B cell 
lymphoma. In the plot below, we have taken mean standard uptake value of liver before 
treatment and one month after treatment. At the same time each patient went through 
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liver function tests on the same day of the scan. The result is shown in the plot below. 
 
Figure 4-3: Mean SUV and ALT  
 Plot 4-3 shows changes in mean standard uptake value at baseline and one month after 
chemotherapy on the left and also changes in alanine aminotransferase value at baseline 
and one month after chemotherapy on the right. 
 
 
  When liver mean SUV is compared between the baseline period 
and interim period, it increased from 1.95 to 2.10, this value has been discussed more 
elaborately in the previous section, whereas in the same period the mean value of 
alanine aminotransferase has decreased slightly from to 23.63 to 23.10. A T paired test 
was carried out to see if the change is significant and up to a considerable level. 
 
 
Table 7: Paired T Test ALT before and after chemotherapy 
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  We assumed significant value to be below 0.05 i.e. (α<0.05). P 
value of 0.874 was obtained in ALT T paired test which indicates and statistically 
shows that the there is no significant change in alanine aminotransferase value before 
chemotherapy and after chemotherapy. 
 Correlation between mean SUV at baseline and alanine 
aminotreansferase was calculated using medcalc software and correlation coefficient 
was -0.4875 with significance level 0.0401 at baseline.  
 
 
Figure 4-4: ALT and Mean SUV correlation at baseline 
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Figure 4-5: ALT and Mean SUV one month after chemotherapy correlation 
 Similarly correlation coefficient one month after administrating 
chemotherapy was -0.1356 with significance level of 0.5917. As we can see there is 
negative correlation in both the study before and after chemotherapy. Howevr, the 
correlation in both the cases is insignificant.  
 
4.4.2 Maximum SUV and Alanine Aminotransferase 
 
  The relation between liver maximum SUV and alanine 
aminotransferase was also analyzed to see the possibility of some interesting relation or 
pattern. Analyzing the mean of maximum liver SUV, the interim mean of liver 
maximum SUV seen was 3.533 which decreased when compared to baseline values of 
4.0275. When paired T test was used using the same hypothesis as mentioned above to 
see the significance level in the obtained values between baseline and interim period, 
the P value obtained was 0.475. This shows no significant change in the liver maximum 
SUV. As we calculated above the significance value for ALT before and after treatment 
is 0.874.   Even though both the mean of liver maximum SUV and mean alanine 
aminotransferase values decreased from baseline to the interim period, those values did 
not change significantly.  
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Figure 4-6: : Maximum SUV and ALT 
Plot 4-6 showing changes in maximum standard uptake value at baseline and one month 
after chemotherapy on the left of the plot and also changes in alanine aminotransferase 
value at baseline and one month after chemotherapy on the right. 
 Correalation between maximum suv and alanine 
aminotransferase was calculated using MedCalc statistical software, and the obtained 
correalation coefficient was -0.3785 with significance level of 0.1214. 
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Figure 4-7: ALT AND SUV max at baseline 
 Similarly correlation coefficient one month after chemotherapy 
between maximum liver SUV and alanine aminotransferase was -0.1635 with 
significance level of 0.5167.  
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Figure 4-8: ALT and SUV max correlation one month after chemotherapy. 
 
4.4.3 Mean SUV and Alkaline Phosphatase 
 
  Another liver function test that was included in the study was 
alkaline phosphatase. Alkaline phosphatase (AFOS) is mainly found in liver and bones. 
The abnormal AFOS level indicates some problem related to bones or normal 
functioning of the liver. So, abnormal AFOS level can give us some indication 
regarding diseased, damaged liver under some stress. AFOS values were obtained from 
a blood sample from the patient before the chemotherapy i.e. baseline and one month 
after chemotherapy when the PET/CT scan was taken. As with ALT values we compare 
it with mean SUV of the liver.  
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Figure 4-9: Mean SUV and AFOS 
Plot 4-9 showing changes in mean standard uptake value at baseline and one month 
after chemotherapy on the left and also changes in alkaline phosphatase value at 
baseline and one month after chemotherapy on the right. 
 
 As we have discussed above the mean liver SUV has increased 
from baseline to interim PET level in the same period mean AFOS level has decreased 
from 80.474 at baseline level to 70 at interim level. The paired T test was used to see if 
the change in AFOS value was significant. 
 
Table 8: Paired T test AFOS before and after chemotherapy  
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 P value of 0.101 was obtained which is greater than our assumed 
alpha value of 0.05. So, no significant change in AFOS value can be seen from the 
baseline period to interim periods after chemotherapy.   
 Correation coefficient between mean liver suv and alkaline 
phosphatase was calculated before and after chemotherapy using MedCalc statistical 
software.  
 
Figure 4-10: AFOS and mean SUV at baseline correlation 
 Correlation coefficient changed from 0.2170 to -0.2069 before 
and one month after chemotherapy respectively. The shift from positive to negative 
correlation after chemotherapy is noticeable. However, the change was not significant 
with significance level of 0.3870 at baseline and 0.4257 one month after chemotherapy.  
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Figure 4-11: AFOS and mean SUV one month after chemotherapy correlation 
 
4.4.4 Maximum SUV and Alkaline Phosphatase 
 
 Maximum liver standard uptake value and alkaline phosphatase 
level was also compared and analyzed to see if we could see some noticeable difference 
or change. The maximum liver SUV decreased from baseline to interim from 4.0275 to 
3.5338 respectively. When paired T test was used to see the significance level in the 
obtained values between baseline and interim period, the P value obtained was 0.475, 
which shows no significant change. Similarly, as we did paired t test for AFOS as 
mentioned above and obtained a value of 0.101. It can be seen that even though both the 
maximum liver SUV value and AFOS value decreased from baseline to interim period 
the change in their values was not so significant. Hence, we get an indication that even 
though the value changed from baseline to interim period the change in values seen is 
insignificant.   
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Figure 4-12: Maximum SUV and AFOS 
Plot 4-12 showing changes in maximum standard uptake value at baseline and one 
month after chemotherapy  on the left and also changes in alkaline phosphatase value at 
baseline and one month after chemotherapy on the right. 
 
 The correlation between maximum SUV and alkaline phosphatase was 
performed and we obtained correlation coefficient of -0.1469 and -0.1676 at baseline 
and one month after chemotherapy using MedCalc statistical software. However, 
correlation in both the instances were insignificant. 
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Figure 4-13: AFOS and SUV max at baseline correlation. 
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Figure 4-14: AFOS and SUV max one month after chemotherapy correlation. 
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5 Discussion 
 
 
 The present thesis study is to ascertain if there are changes in F-18 FDG uptake 
in the liver after chemotherapy R-CHOP on a patient having diffuse large B-cell non-
Hodgkin’s lymphoma. In our study, liver SUVmean and SUVmax is compared to 
before chemotherapy with one week after, one month after and four months after 
chemotherapy. The present study shows that there was no significant change in 
SUVmax and SUVmean value one week after chemotherapy, but the changes were 
significant for SUV mean one month and four months after chemotherapy when 
compared to baseline. The SUVmax and SUVmean values increased during the latter 
period.  
 This result partly corroborates with similar studies in this field [25] [48]. A 
study conducted by Ceriani et al., where 50 patients with DLBCL and treated with R-
CHOP6 and R-CHOP demonstrated similar result  the study showed a noticeable 
increase in the mean SUV from basal to interim PET i.e. after 2 cycles of chemotherapy 
which approximates E4 in the present study, but normalized on final PET scan i.e. 6 
cycle of chemotherapy [5]. Ceriani et al. treated their patients with R-MACOP-B/R-
VACOP-B and R-CHOP, whereas the patients in our study were treated only with R-
CHOP and there was no relation documented that showed an effect in liver was solely 
due to chemotherapy [25]. A similar study by Chiaravalloti et al. to assess intrapatient 
liver and mediastinal blood pool 18F-FDG uptake in patients with Hodgkin’s lymphoma 
after ABVD chemotherapy showed similar results to the present study. An increase in 
SUV mean uptake between PET 0 and PET 2, was seen and the changes seen were 
significant which approximates E1 and E4 in our study [48].  
 SUVmax values did not change significantly when compared before and after 
different cycles of chemotherapy. A similar study by B. Kaya et al demonstrates similar 
findings where there were some changes between SUV maximum at baseline, interim 
and final PET but the changes were not  significant [25]. Study by Ceriani et al. showed 
similar finding when compared to basal PET/CT SUV maximum to PET/CT scan 3-4 
months after chemotherapy [5]. There was a slight increase in SUV max during this 
period, but the increase was not significant in our study. Study by Chiaravalloti et al. 
also showed an increase in SUV max from basal to 2-3 months after ABVD 
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chemotherapy, however the change seen in the SUV max during that period was 
significant [48].  
 Difference in SUV value in different studies were due to different segmentation 
method. Ceriani et al. used 2-D circular ROI in right lobe of liver, Chiaravalloti used 3-
D ROI, whereas in our study manual segmentation was applied for all the slices along 
volume of the liver. The segmentation method plays a vital factor in obtaining 
SUVmean and SUVmax value. In our study the baseline SUVmean was 1.95 which 
almost matched 1.98 in a study by ceriani et al. The interim PET/CT scan after 1 month 
(SUVmean = 2.108) also closely resembles an interim PET study by Ceriani et al. 
(SUVmean = 2.17). In case of final PET scan which was done by Ceriani et al. 6-7 
month after chemotherapy the SUVmean has decreased to 2. However, in our case the 
final PET/CT scan was taken 3-4 months after chemotherapy and the SUVmean value 
was almost similar to previous scan i.e. (2.10 and 2.17). The study could have been 
more meaningful if the PET/CT scan of the patient could be acquired 6 months and one 
year after administrating chemotherapy.  
 Many previous studies have failed to include liver function test and compare the 
results with the PET/CT scan, which we have been able to include in our study. Alanine 
aminotransferase value decreased slightly over the period of one month after initiating 
chemotherapy, whereas the liver SUVmean increased slightly during the same period, 
both of the changes were insignificant. Abnormal ALT values generally indicate some 
problem in normal liver functioning. As the change in ALT value was insignificant it is 
difficult to derive any concrete analysis, and to ascertain the change was due to 
chemotherapy.  
 We analyze the correlation of mean and maximum liver standard uptake value 
with liver function test ALT and AFOS. When mean SUV and ALT is correlated we 
can see that before chemotherapy, they are weakly related with a correlation coefficient 
of -0.4875. If we see the correlation coefficient one month after chemotherapy the 
correlation becomes weaker and almost no correlation exists between mean liver SUV 
and alanine aminotransferase. In case of maximum liver SUV and alanine 
aminotransferase weak correlation exists before chemotherapy with -0.3785 and the 
correlation becomes weaker one month after chemotherapy as illustrated in figure 4-7. 
 In case of mean liver SUV and alkaline phosphatase positive correlation 
coefficient changed to negative one month after chemotherapy, i.e. from 0.2170 to -
0.2069. However, both the correlation coefficient is weakly related. Similarly, 
maximum liver SUV and alkaline phosphatase are also weakly related at baseline and 
one month after chemotherapy with correlation coefficient of -0.1469 and -0-1676 
respectively. Alkaline phosphatase a vital parameter for liver function test also 
decreased from baseline to one month after chemotherapy. The change was 
considerable,  but not significant. ALT and AFOS are a major enzyme present in the 
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liver and some decrease in levels of both the enzyme has been documented, but a 
change in insignificant amount limits this study to derive any conclusion. 
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6 Conclusion 
 
 
 The main purpose of the thesis was to see the change in standard uptake value of 
liver before and after chemotherapy and compare it to laboratory values concerning 
liver function test alanine aminotransferase and alkaline phosphatase. The mean 
standard uptake value did not change for a week after chemotherapy, but scanning after 
one month and four months of chemotherapy showed significant changes in mean 
standard uptake value of liver when compared with the baseline. There was a decrease 
in maximum standard uptake value at baseline and after chemotherapy, but the change 
was not significant. Mean SUV of liver increased after chemotherapy, whereas alanine 
aminotransferase and alkaline phosphatase value have both decreased one month after 
chemotherapy, both the changes were not significant. Maximum SUV, alanine 
aminotransferase and alkaline phosphatase value decreased one month after 
chemotherapy, but changes were not significant.  
 The present study shows that there are changes in mean liver 18F-FDG uptake 
before and after chemotherapy. However, researchers should be careful as to deriving 
interpretation of this study and making therapeutic strategies for treatment.  
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7 Appendix 
Mean Liver SUV 
 
 
Maximum Liver SUV 
 
 
SUV mean and ALT: 
 
Descriptives 
 Statistic Std. Error 
MeanBaseline Mean 1,9541 ,10129 
95% Confidence Interval 
for Mean 
Lower Bound 1,7413  
Upper Bound 2,1669  
5% Trimmed Mean 1,9283  
Median 1,9690  
Variance ,195  
Std. Deviation ,44153  
Minimum 1,30  
Maximum 3,08  
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Range 1,78  
Interquartile Range ,44  
Skewness ,795 ,524 
Kurtosis 1,129 1,014 
MeanInterim Mean 2,1088 ,08355 
95% Confidence Interval 
for Mean 
Lower Bound 1,9332  
Upper Bound 2,2843  
5% Trimmed Mean 2,0948  
Median 2,0340  
Variance ,133  
Std. Deviation ,36418  
Minimum 1,51  
Maximum 2,96  
Range 1,46  
Interquartile Range ,44  
Skewness ,403 ,524 
Kurtosis ,253 1,014 
ALTBaseline Mean 2,3632 ,27659 
95% Confidence Interval 
for Mean 
Lower Bound 1,7821  
Upper Bound 2,9443  
5% Trimmed Mean 2,2313  
Median 2,0000  
Variance 1,454  
Std. Deviation 1,20564  
Minimum 1,30  
Maximum 5,80  
Range 4,50  
Interquartile Range 1,50  
Skewness 1,570 ,524 
Kurtosis 2,391 1,014 
ALTInterim Mean 2,3105 ,22333 
95% Confidence Interval 
for Mean 
Lower Bound 1,8413  
Upper Bound 2,7797  
5% Trimmed Mean 2,2561  
Median 2,0000  
Variance ,948  
Std. Deviation ,97348  
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Minimum 1,20  
Maximum 4,40  
Range 3,20  
Interquartile Range 1,10  
Skewness 1,206 ,524 
Kurtosis ,477 1,014 
 
 
Paired T test Alanine Aminotransferase at baseline and one month after chemotherapy. 
 
 
 
 
 
SUV max and ALT 
 
Descriptives 
 Statistic Std. Error 
MaxBaseline Mean 4,0275 ,65741 
95% Confidence Interval 
for Mean 
Lower Bound 2,6463  
Upper Bound 5,4086  
5% Trimmed Mean 3,5112  
Median 3,3590  
Variance 8,212  
Std. Deviation 2,86559  
Minimum 2,25  
Maximum 15,10  
Range 12,84  
Interquartile Range 1,26  
Skewness 3,536 ,524 
Kurtosis 13,775 1,014 
MaxInterim Mean 3,5338 ,20797 
95% Confidence Interval Lower Bound 3,0969  
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for Mean Upper Bound 3,9707  
5% Trimmed Mean 3,4912  
Median 3,5810  
Variance ,822  
Std. Deviation ,90650  
Minimum 2,00  
Maximum 5,84  
Range 3,84  
Interquartile Range 1,25  
Skewness ,679 ,524 
Kurtosis ,921 1,014 
ALTBaseline Mean 2,3632 ,27659 
95% Confidence Interval 
for Mean 
Lower Bound 1,7821  
Upper Bound 2,9443  
5% Trimmed Mean 2,2313  
Median 2,0000  
Variance 1,454  
Std. Deviation 1,20564  
Minimum 1,30  
Maximum 5,80  
Range 4,50  
Interquartile Range 1,50  
Skewness 1,570 ,524 
Kurtosis 2,391 1,014 
ALTInterim Mean 2,3105 ,22333 
95% Confidence Interval 
for Mean 
Lower Bound 1,8413  
Upper Bound 2,7797  
5% Trimmed Mean 2,2561  
Median 2,0000  
Variance ,948  
Std. Deviation ,97348  
Minimum 1,20  
Maximum 4,40  
Range 3,20  
Interquartile Range 1,10  
Skewness 1,206 ,524 
Kurtosis ,477 1,014 
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Mean liver SUV and AFOS 
 Statistic Std. Error 
MeanBaseline Mean 1,9541 ,10129 
95% Confidence Interval 
for Mean 
Lower Bound 1,7413  
Upper Bound 2,1669  
5% Trimmed Mean 1,9283  
Median 1,9690  
Variance ,195  
Std. Deviation ,44153  
Minimum 1,30  
Maximum 3,08  
Range 1,78  
Interquartile Range ,44  
Skewness ,795 ,524 
Kurtosis 1,129 1,014 
MeanInterim Mean 2,1088 ,08355 
95% Confidence Interval 
for Mean 
Lower Bound 1,9332  
Upper Bound 2,2843  
5% Trimmed Mean 2,0948  
Median 2,0340  
Variance ,133  
Std. Deviation ,36418  
Minimum 1,51  
Maximum 2,96  
Range 1,46  
Interquartile Range ,44  
Skewness ,403 ,524 
Kurtosis ,253 1,014 
AFOSbaseline Mean 8,0474 ,77537 
95% Confidence Interval 
for Mean 
Lower Bound 6,4184  
Upper Bound 9,6764  
5% Trimmed Mean 7,6360  
Median 6,8000  
Variance 11,423  
P a g e  | 56 
 
 
 
Std. Deviation 3,37974  
Minimum 5,00  
Maximum 18,50  
Range 13,50  
Interquartile Range 3,60  
Skewness 2,003 ,524 
Kurtosis 4,240 1,014 
AFOSinterim Mean 7,0000 ,50245 
95% Confidence Interval 
for Mean 
Lower Bound 5,9444  
Upper Bound 8,0556  
5% Trimmed Mean 6,8389  
Median 6,3000  
Variance 4,797  
Std. Deviation 2,19013  
Minimum 4,40  
Maximum 12,50  
Range 8,10  
Interquartile Range 3,20  
Skewness 1,155 ,524 
Kurtosis ,844 1,014 
 
 
AFOS baseline and one month after chemotherapy 
 
 
 
Maximum liver SUV and AFOS 
 
 Statistic Std. Error 
MaxBaseline Mean 4,0275 ,65741 
95% Confidence Interval 
for Mean 
Lower Bound 2,6463  
Upper Bound 5,4086  
5% Trimmed Mean 3,5112  
Median 3,3590  
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Variance 8,212  
Std. Deviation 2,86559  
Minimum 2,25  
Maximum 15,10  
Range 12,84  
Interquartile Range 1,26  
Skewness 3,536 ,524 
Kurtosis 13,775 1,014 
MaxInterim Mean 3,5338 ,20797 
95% Confidence Interval 
for Mean 
Lower Bound 3,0969  
Upper Bound 3,9707  
5% Trimmed Mean 3,4912  
Median 3,5810  
Variance ,822  
Std. Deviation ,90650  
Minimum 2,00  
Maximum 5,84  
Range 3,84  
Interquartile Range 1,25  
Skewness ,679 ,524 
Kurtosis ,921 1,014 
AFOSbaseline Mean 8,0474 ,77537 
95% Confidence Interval 
for Mean 
Lower Bound 6,4184  
Upper Bound 9,6764  
5% Trimmed Mean 7,6360  
Median 6,8000  
Variance 11,423  
Std. Deviation 3,37974  
Minimum 5,00  
Maximum 18,50  
Range 13,50  
Interquartile Range 3,60  
Skewness 2,003 ,524 
Kurtosis 4,240 1,014 
AFOSinterim Mean 7,0000 ,50245 
95% Confidence Interval 
for Mean 
Lower Bound 5,9444  
Upper Bound 8,0556  
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5% Trimmed Mean 6,8389  
Median 6,3000  
Variance 4,797  
Std. Deviation 2,19013  
Minimum 4,40  
Maximum 12,50  
Range 8,10  
Interquartile Range 3,20  
Skewness 1,155 ,524 
Kurtosis ,844 1,014 
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